GlassScriptPhysician profile
Danielle A Wyant
NPI 1760651905
$8,681.56
in general payments reported to CMS, 2019-2025
65 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 77% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $298 · 2021: $65.39 · 2022: $1,146 · 2023: $1,595 · 2024: $2,267 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,558.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,260.53 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $456.33 | 2022-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $375.00 | 2022-2025 | Epidiolex |
| Livanova USA, INC. | $374.03 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $358.04 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $354.85 | 2019-2022 | |
| Abbvie INC. | $337.38 | 2023-2025 | Qulipta, Ubrelvy, Botox |
| Alexion Pharmaceuticals, INC. | $304.15 | 2019-2025 | Ultomiris |
| Avadel Cns Pharmaceuticals, LLC | $276.92 | 2024-2025 | Lumryz |
| Sumitomo Pharma America, INC. | $242.60 | 2023-2024 | Aptiom |
| Ironshore Pharmaceuticals INC. | $223.84 | 2019-2024 | Jornay Pm |
| Aquestive Therapeutics, INC. | $216.76 | 2019-2024 | |
| Corium, LLC | $209.17 | 2022-2024 | Azstarys |
| Aucta Pharmaceuticals, INC. | $170.31 | 2024-2025 | Motpoly Xr |
| Supernus Pharmaceuticals, INC. | $130.39 | 2019 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Wyant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.